tickdelta
Sign in

Tickdelta is free for now. Sign up and get Pro free

← Screener

VRTXVertex Pharmaceuticals

Health care · Pharmaceuticals · Nasdaq

We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. 10-K, Item 1

Employees
6,400
Headquarters
Boston, MA
CEO
Reshma Kewalramani
Next results
around Feb 11, 2027
Compare with peers → Embed

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. Below: what the staff asked VRTX, and the company's answer to each question, quoted from the letters. A question is not an accusation; most reviews end with the company adding detail to its next filing.

Schedule 14A

2022-09-20 to 2022-10-04 · 3 questions · 1 letter from the SEC, 1 from the company
Review closed 2022-10-04
Controls
Definitive Proxy Statement on Schedule 14A filed April 7, 2022 · General
SEC asked (1)
Please expand your discussion of the reasons you believe that your leadership structure is appropriate, addressing your specific characteristics or circumstances. In your discussion, please also address the circumstances under which you would consider having the Chair and CEO roles filled by a single individual, when shareholders would be notified of any such change, and whether you will seek prior input from
Rest of the question

shareholders. Please also address how the experience of your Lead Independent Director is brought to bear in connection with your board’s role in risk oversight.

VRTX answered
The Company acknowledges the Staff’s comment, and will enhance its future proxy disclosures to expand its discussion of the reasons it believes its leadership structure is appropriate. The discussion will address, among other matters, the circumstances under which the Company would consider having the Chair and CEO roles filled by a single individual, when shareholders would be notified of any such change, and whether the Company will seek prior input from its shareholders.
Rest of the answer

The discussion will also address how the experience of the Company’s Lead Independent Director is brought to bear in connection with the board’s role in risk oversight.

Securities and Exchange Commission

-

Read in the reply ↗
Definitive Proxy Statement on Schedule 14A filed April 7, 2022 · General
SEC asked (2)
Please expand upon the role that your Lead Independent Director plays in the leadership of the board. For example, please enhance your disclosure to address whether or not your Lead Independent Director may: • represent the board in communications with shareholders and other stakeholders; • require board consideration of, and/or override your CEO on, any risk matters; or • provide input on design of the board itself.
VRTX answered
The Company acknowledges the Staff’s comment, and will enhance its future proxy disclosures to expand its discussion of the role its Lead Independent Director plays in the leadership of the board. The disclosure will address, among other matters, whether or not its Lead Independent Director may: (i) represent the board in communications with shareholders or other stakeholders, (ii) require board consideration of, and/or override the Company’s CEO on, any risk matters, and

(iii) provide input on the design of the board itself. Read in the reply ↗
Definitive Proxy Statement on Schedule 14A filed April 7, 2022 · General
SEC asked (3)
Please expand upon how your board administers its risk oversight function. For example, please disclose: • the timeframe over which you evaluate risks (e.g., short-term, intermediate-term, or long-term) and how you apply different oversight standards based upon the immediacy of the risk assessed; • whether you consult with outside advisors and experts to anticipate future threats and trends, and how often you
Rest of the question

re-assess your risk environment; • whether you have a Chief Compliance Officer and to whom this position reports; and • how your risk oversight process aligns with your disclosure controls and procedure.

VRTX answered
acknowledges the Staff’s comment, and will enhance its future proxy disclosures to expand upon how its board administers its risk oversight function. The disclosures will address, among other matters, the timeframe over which the Company evaluates risks and how its applies different oversight standards based upon the immediacy of the risks assessed, whether it consults with outside advisors and experts to anticipate future threats and trends and how often it re-assesses its risk environment, whether it has a Chief Compliance Officer and to whom this position reports, and how its risk
Rest of the answer

oversight process aligns with its disclosure controls and procedures.

Read in the reply ↗

Also in this review: closing letter, 2022-10-04

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 9 letters filed since 2022-09-20. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Work on VRTX in a spreadsheet: Excel workbook (a sheet per section, ten years by column, charts, links to the filings) · CSV. For a Google Sheet that stays up to date, paste =IMPORTDATA("https://tickdelta.com/company/VRTX/export.csv") into a cell.